{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T01:07:05Z","timestamp":1782608825583,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T00:00:00Z","timestamp":1516752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T00:00:00Z","timestamp":1516752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"crossref","award":["TCVGH-NHRI10603"],"award-info":[{"award-number":["TCVGH-NHRI10603"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"crossref","award":["TCVGH-1067310C"],"award-info":[{"award-number":["TCVGH-1067310C"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"crossref","award":["TCVGH-FCU1068205"],"award-info":[{"award-number":["TCVGH-FCU1068205"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"crossref","award":["TCVGH-YM1060201"],"award-info":[{"award-number":["TCVGH-YM1060201"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"crossref","award":["TCVGH-VTA106PREM1"],"award-info":[{"award-number":["TCVGH-VTA106PREM1"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"crossref","award":["TCVGH-1043109C"],"award-info":[{"award-number":["TCVGH-1043109C"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"crossref","award":["TCVGH-1053108C"],"award-info":[{"award-number":["TCVGH-1053108C"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"crossref","award":["TCVGH-VHCY1068606"],"award-info":[{"award-number":["TCVGH-VHCY1068606"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"crossref","award":["TCVGH-1033103C"],"award-info":[{"award-number":["TCVGH-1033103C"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"crossref","award":["TCVGH-1033105C"],"award-info":[{"award-number":["TCVGH-1033105C"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001868","name":"National Science Council, Taiwan","doi-asserted-by":"crossref","award":["102-2314-B-075A-009-MY2"],"award-info":[{"award-number":["102-2314-B-075A-009-MY2"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001868","name":"National Science Council, Taiwan","doi-asserted-by":"crossref","award":["104-2314-B-367-001"],"award-info":[{"award-number":["104-2314-B-367-001"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001868","name":"National Science Council, Taiwan","doi-asserted-by":"crossref","award":["105-2314-B-367-001-MY3"],"award-info":[{"award-number":["105-2314-B-367-001-MY3"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Metformin is the standard first-line drug for patients with Type 2 diabetes (T2DM). However, the optimal second-line oral anti-diabetic agent (ADA) remains unclear. We investigated the cardiovascular risk of various ADAs used as add-on medication to metformin in T2DM patients from a nationwide cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>T2DM patients using different add-on oral ADAs after an initial metformin therapy of &gt;\u00a090\u00a0days were identified from the Taiwan National Health Insurance Database. Five classes of ADAs, including sulphonylureas (SU), glinides, thiazolidinediones (TZD), alpha-glucosidase inhibitors (AGI), and dipeptidyl peptidase-4 inhibitors (DPP-4I) were selected for analysis. The reference group was the SU added to metformin. Patients were excluded if aged\u00a0&lt;\u00a020\u00a0years, had a history of stroke or acute coronary syndrome (ACS), or were receiving insulin treatment. The primary outcomes included any major adverse cardiovascular event (MACE) including ACS, ischemic\/hemorrhagic stroke, and death. A Cox regression model was used to estimate the hazard ratio (HR) for MACE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 26,742 patients receiving their add-on drug to metformin of either SU (n\u00a0=\u00a024,277), glinides (n\u00a0=\u00a0962), TZD (n\u00a0=\u00a0581), AGI (n\u00a0=\u00a0808), or DPP-4I (n\u00a0=\u00a0114) were analyzed. After a mean follow-up duration of 6.6\u00a0\u00b1\u00a03.4\u00a0years, a total of 4775 MACEs occurred. Compared with the SU+metformin group (reference), the TZD+metformin (adjusted HR: 0.66; 95% CI 0.50\u20130.88, p\u00a0=\u00a00.004) and AGI+metformin (adjusted HR: 0.74; 95% CI 0.59\u20130.94, p\u00a0=\u00a00.01) groups showed a significantly lower risk of MACE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Both TZD and AGI, when used as an add-on drug to metformin were associated with lower MACE risk when compared with SU added to metformin in this retrospective cohort study.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> CE13152B-3. Registered 7 Mar, 2013, retrospectively registered<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-018-0663-6","type":"journal-article","created":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T08:12:24Z","timestamp":1516781544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study"],"prefix":"10.1186","volume":"17","author":[{"given":"Cheng-Wei","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu-Leng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiunn-Cherng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-7139","authenticated-orcid":false,"given":"Yu-Cheng","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Ying","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hung","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Chieh","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu-Pin","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Long","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Heng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsu-Juey","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,24]]},"reference":[{"key":"663_CR1","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1093\/eurheartj\/ehr154","volume":"32","author":"MK Rutter","year":"2011","unstructured":"Rutter MK, Nesto RW. Blood pressure, lipids and glucose in Type 2 diabetes: how low should we go? Re-discovering personalized care. Eur Heart J. 2011;32:2247\u201355.","journal-title":"Eur Heart J"},{"key":"663_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12933-017-0499-5","volume":"16","author":"J Xu","year":"2017","unstructured":"Xu J, Rajaratnam R. Cardiovascular safety of non-insulin pharmacotherapy for Type 2 diabetes. Cardiovasc Diabetol. 2017;16:18.","journal-title":"Cardiovasc Diabetol"},{"key":"663_CR3","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet. 1998;352:854\u201365.","journal-title":"Lancet"},{"key":"663_CR4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in Type 2 diabetes. N Engl J Med. 2008;359:1577\u201389.","journal-title":"N Engl J Med"},{"key":"663_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in Type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140\u20139.","journal-title":"Diabetes Care"},{"key":"663_CR6","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","volume":"281","author":"RC Turner","year":"1999","unstructured":"Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with Type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005\u201312.","journal-title":"JAMA"},{"key":"663_CR7","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMicm066227","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2008;358:2560\u201372.","journal-title":"N Engl J Med"},{"key":"663_CR8","doi-asserted-by":"publisher","first-page":"e013927","DOI":"10.1136\/bmjopen-2016-013927","volume":"7","author":"HW Liao","year":"2017","unstructured":"Liao HW, Saver JL, Wu YL, Chen TH, Lee M, Ovbiagele B. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and Type 2 diabetes: a systematic review and meta-analysis. BMJ Open. 2017;7:e013927.","journal-title":"BMJ Open"},{"key":"663_CR9","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279\u201389.","journal-title":"Lancet"},{"key":"663_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12933-017-0623-6","volume":"16","author":"Y Tian","year":"2017","unstructured":"Tian Y, Chen T, Wu Y, et al. Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17\/Treg balance in AMPK-dependent mechanisms. Cardiovasc Diabetol. 2017;16:140.","journal-title":"Cardiovasc Diabetol"},{"key":"663_CR11","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1001\/jama.290.4.486","volume":"290","author":"JL Chiasson","year":"2003","unstructured":"Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486\u201394.","journal-title":"JAMA"},{"key":"663_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12933-017-0571-1","volume":"16","author":"M Shimabukuro","year":"2017","unstructured":"Shimabukuro M, Tanaka A, Sata M, et al. alpha-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with Type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study. Cardiovasc Diabetol. 2017;16:86.","journal-title":"Cardiovasc Diabetol"},{"key":"663_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2015;373:232\u201342.","journal-title":"N Engl J Med"},{"key":"663_CR14","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with Type 2 diabetes mellitus. N Engl J Med. 2013;369:1317\u201326.","journal-title":"N Engl J Med"},{"key":"663_CR15","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with Type 2 diabetes. N Engl J Med. 2013;369:1327\u201335.","journal-title":"N Engl J Med"},{"key":"663_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1001\/jama.2016.9400","volume":"316","author":"SC Palmer","year":"2016","unstructured":"Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with Type 2 diabetes: a meta-analysis. JAMA. 2016;316:313\u201324.","journal-title":"JAMA"},{"key":"663_CR17","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.2337\/dc13-0356","volume":"36","author":"DM Nathan","year":"2013","unstructured":"Nathan DM, Buse JB, Kahn SE, et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2013;36:2254\u201361.","journal-title":"Diabetes Care"},{"key":"663_CR18","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/dom.12704","volume":"18","author":"N Ekstrom","year":"2016","unstructured":"Ekstrom N, Svensson AM, Miftaraj M, et al. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in Type 2 diabetes: report from the Swedish National Diabetes Register. Diabetes Obes Metab. 2016;18:990\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"663_CR19","doi-asserted-by":"publisher","first-page":"e0124287","DOI":"10.1371\/journal.pone.0124287","volume":"10","author":"JM Seong","year":"2015","unstructured":"Seong JM, Choi NK, Shin JY, et al. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for Type 2 diabetes: a population-based cohort study. PLoS ONE. 2015;10:e0124287.","journal-title":"PLoS ONE"},{"key":"663_CR20","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/dme.13384","volume":"34","author":"KH Ha","year":"2017","unstructured":"Ha KH, Kim B, Choi H, Kim DJ, Kim HC. Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data. Diabet Med. 2017;34:1235\u201343.","journal-title":"Diabet Med"},{"key":"663_CR21","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1111\/dme.12800","volume":"32","author":"YC Chang","year":"2015","unstructured":"Chang YC, Chuang LM, Lin JW, Chen ST, Lai MS, Chang CH. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study. Diabet Med. 2015;32:1460\u20139.","journal-title":"Diabet Med"},{"key":"663_CR22","doi-asserted-by":"publisher","first-page":"11442","DOI":"10.1038\/srep11442","volume":"5","author":"CY Hung","year":"2015","unstructured":"Hung CY, Hsieh YC, Li CH, Huang JL, Lin CH, Wu TJ. Age and CHADS2 score predict the effectiveness of renin-angiotensin system blockers on primary prevention of atrial fibrillation. Sci Rep. 2015;5:11442.","journal-title":"Sci Rep"},{"key":"663_CR23","doi-asserted-by":"publisher","first-page":"e3721","DOI":"10.1097\/MD.0000000000003721","volume":"95","author":"YC Hsieh","year":"2016","unstructured":"Hsieh YC, Hung CY, Li CH, et al. Angiotensin-receptor blocker, angiotensin-converting enzyme inhibitor, and risks of atrial fibrillation: a nationwide cohort study. Medicine (Baltimore). 2016;95:e3721.","journal-title":"Medicine (Baltimore)"},{"key":"663_CR24","doi-asserted-by":"publisher","first-page":"e000059","DOI":"10.1136\/bmjdrc-2014-000059","volume":"3","author":"N Ekstrom","year":"2015","unstructured":"Ekstrom N, Svensson AM, Miftaraj M, et al. Durability of oral hypoglycemic agents in drug naive patients with Type 2 diabetes: report from the Swedish National Diabetes Register (NDR). BMJ Open Diabetes Res Care. 2015;3:e000059.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"663_CR25","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Pharmacologic approaches to glycemic treatment. Sec. 8. In: Standards of Medical Care in Diabetes\u20142017. Diabetes Care, Vol. 40; 2017. pp. S64\u201374.","DOI":"10.2337\/dc17-S011"},{"key":"663_CR26","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/dom.12692","volume":"18","author":"SS Zghebi","year":"2016","unstructured":"Zghebi SS, Steinke DT, Rutter MK, Emsley RA, Ashcroft DM. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records. Diabetes Obes Metab. 2016;18:916\u201324.","journal-title":"Diabetes Obes Metab"},{"key":"663_CR27","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMra041001","volume":"351","author":"H Yki-Jarvinen","year":"2004","unstructured":"Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106\u201318.","journal-title":"N Engl J Med"},{"key":"663_CR28","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","volume":"374","author":"WN Kernan","year":"2016","unstructured":"Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321\u201331.","journal-title":"N Engl J Med"},{"key":"663_CR29","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","volume":"5","author":"O Vaccaro","year":"2017","unstructured":"Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with Type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5:887\u201397.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"663_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000353679","volume":"36","author":"CJ Lu","year":"2013","unstructured":"Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study. Cerebrovasc Dis. 2013;36:145\u201351.","journal-title":"Cerebrovasc Dis"},{"key":"663_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12933-017-0617-4","volume":"16","author":"M de Jong","year":"2017","unstructured":"de Jong M, van der Worp HB, van der Graaf Y, Visseren FLJ, Westerink J. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovasc Diabetol. 2017;16:134.","journal-title":"Cardiovasc Diabetol"},{"key":"663_CR32","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457\u201371.","journal-title":"N Engl J Med"},{"key":"663_CR33","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1161\/CIRCRESAHA.110.236687","volume":"109","author":"E Murphy","year":"2011","unstructured":"Murphy E. Estrogen signaling and cardiovascular disease. Circ Res. 2011;109:687\u201396.","journal-title":"Circ Res"},{"key":"663_CR34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1677\/joe.0.1820229","volume":"182","author":"AG Gunin","year":"2004","unstructured":"Gunin AG, Bitter AD, Demakov AB, Vasilieva EN, Suslonova NV. Effects of peroxisome proliferator activated receptors-alpha and -gamma agonists on estradiol-induced proliferation and hyperplasia formation in the mouse uterus. J Endocrinol. 2004;182:229\u201339.","journal-title":"J Endocrinol"},{"key":"663_CR35","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1097\/00004872-200207000-00028","volume":"20","author":"A El Midaoui","year":"2002","unstructured":"El Midaoui A, Wu R, de Champlain J. Prevention of hypertension, hyperglycemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats. J Hypertens. 2002;20:1407\u201312.","journal-title":"J Hypertens"},{"key":"663_CR36","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.2337\/diacare.21.9.1529","volume":"21","author":"A Ceriello","year":"1998","unstructured":"Ceriello A, Bortolotti N, Motz E, et al. Meal-generated oxidative stress in Type 2 diabetic patients. Diabetes Care. 1998;21:1529\u201333.","journal-title":"Diabetes Care"},{"key":"663_CR37","doi-asserted-by":"publisher","first-page":"348","DOI":"10.2337\/dc08-1411","volume":"32","author":"M Hyvarinen","year":"2009","unstructured":"Hyvarinen M, Qiao Q, Tuomilehto J, et al. Hyperglycemia and stroke mortality: comparison between fasting and 2-h glucose criteria. Diabetes Care. 2009;32:348\u201354.","journal-title":"Diabetes Care"},{"key":"663_CR38","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1161\/01.STR.0000125864.01546.f2","volume":"35","author":"M Hanefeld","year":"2004","unstructured":"Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004;35:1073\u20138.","journal-title":"Stroke"},{"key":"663_CR39","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S2213-8587(17)30309-1","volume":"5","author":"RR Holman","year":"2017","unstructured":"Holman RR, Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:877\u201386.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"663_CR40","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1161\/01.CIR.0000103683.99399.7E","volume":"108","author":"RW Nesto","year":"2003","unstructured":"Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation. 2003;108:2941\u20138.","journal-title":"Circulation"},{"key":"663_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","volume":"34","author":"WB Kannel","year":"1974","unstructured":"Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29\u201334.","journal-title":"Am J Cardiol"},{"key":"663_CR42","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2337\/diacare.27.3.699","volume":"27","author":"AG Bertoni","year":"2004","unstructured":"Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004;27:699\u2013703.","journal-title":"Diabetes Care"},{"key":"663_CR43","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","volume":"298","author":"AM Lincoff","year":"2007","unstructured":"Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298:1180\u20138.","journal-title":"JAMA"},{"key":"663_CR44","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1096\/fj.03-0181fje","volume":"17","author":"G Hong","year":"2003","unstructured":"Hong G, Lockhart A, Davis B, et al. PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells. FASEB J. 2003;17:1966\u20138.","journal-title":"FASEB J"},{"key":"663_CR45","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.diabres.2015.06.005","volume":"109","author":"H Yokoyama","year":"2015","unstructured":"Yokoyama H, Araki S, Kawai K, et al. Pioglitazone treatment and cardiovascular event and death in subjects with Type 2 diabetes without established cardiovascular disease (JDDM 36). Diabetes Res Clin Pract. 2015;109:485\u201392.","journal-title":"Diabetes Res Clin Pract"},{"key":"663_CR46","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1681\/ASN.2008121270","volume":"20","author":"T Ninomiya","year":"2009","unstructured":"Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20:1813\u201321.","journal-title":"J Am Soc Nephrol"},{"key":"663_CR47","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3803\/EnM.2016.31.2.239","volume":"31","author":"JC Bae","year":"2016","unstructured":"Bae JC. Diabetes drugs and cardiovascular safety. Endocrinol Metab (Seoul). 2016;31:239\u201344.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"663_CR48","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"663_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12933-016-0350-4","volume":"15","author":"HT Ou","year":"2016","unstructured":"Ou HT, Chang KC, Li CY, Wu JS. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with Type 2 diabetes: a nation-wide longitudinal study. Cardiovasc Diabetol. 2016;15:41.","journal-title":"Cardiovasc Diabetol"},{"key":"663_CR50","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12933-015-0215-2","volume":"14","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Marx N, Neubacher D, et al. Cardiovascular safety of linagliptin in Type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2015;14:57.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-018-0663-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-018-0663-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-018-0663-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T01:44:17Z","timestamp":1634089457000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-018-0663-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,24]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["663"],"URL":"https:\/\/doi.org\/10.1186\/s12933-018-0663-6","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,24]]},"assertion":[{"value":"31 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"20"}}